The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market. Following the discontinuation of three 5-HT antagonists in late-stage development over 20092010, orexin receptor antagonists now represent the most innovative candidates in the insomnia pipeline. ( http://www.bharatbook.com/detail.asp?id=150623&rt=Insomnia-Market-Forecast.html )
Reasons to Purchase
* Quantify the current and future size of the insomnia market in the seven major pharmaceutical markets.
* Identify potential licensing opportunities based on product portfolios and anticipated market needs.
* Understand the country-specific impact of key events in the insomnia market during the forecast period 2010 to 2019.
Key chapters:
OVERVIEW
This product contains forecasts for prescription insomnia drugs across the seven major markets from 2010 t2019. It has been designed for delivery in an excel data pack format, but for more detail about this disease area please see the accompanying Pipeline and Commercial Insight: Insomnia word document and PowerPoint executive presentation (DMHC2616).
The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.